ME

Medifast IncNYSE MED Stock Report

Last reporting period 30 Sep, 2024

Updated 20 Nov, 2024

Last price

Market cap $B

0.209

Micro

Exchange

XNYS - New York Stock Exchange, Inc

MED Stock Analysis

ME

Avoid

Based on Eyestock quantitative analysis, MED`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

65/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-52.6 %

Greatly overvalued

Market cap $B

0.209

Dividend yield

10.14 %

Shares outstanding

10.845 B

Medifast, Inc. engages in the provision of healthy living products and programs. The company is headquartered in Owings Mills, Maryland and currently employs 874 full-time employees. The firm sells a variety of weight loss, weight management and healthy living products all based on its proprietary formulas under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. Medifast’s product line includes more than 65 consumable options, including, but not limited to, bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. OPTAVIA coaches also counsel their customers on how to develop healthy habits, such as preparing lean and green meals and choosing healthy snacks. Medifast nutritional products are formulated with high-quality ingredients. Medifast’s wholly owned subsidiaries include Jason Pharmaceuticals, Inc., OPTAVIA, LLC, Jason Enterprises, Inc., Jason Properties, LLC, Seven Crondall Associates, LLC, Corporate Events, Inc., OPTAVIA (Hong Kong) Limited, and OPTAVIA (Singapore) PTE. LTD

View Section: Eyestock Rating